Imunon General Counsel Executes Stock Sale Following Salary Conversion

Susan Eylward, serving as the General Counsel and Corporate Secretary for Imunon, Inc. (NASDAQ: IMNN), has executed a transaction involving the disposal of company equity, as documented in a Form 4 filing submitted to the Securities and Exchange Commission. The records indicate that on July 6, 2026, Ms. Eylward sold 920 shares of Imunon common stock. The execution price for these shares was recorded at $1.88 per share, resulting in a total transaction value of $1,729. This sale occurred while the stock was trading at $1.95, a level hovering near its 52-week low of $1.70. Despite the proximity to the yearly low, the equity has demonstrated recent momentum, gaining 11% over the preceding week. Market analysis from InvestingPro suggests the stock may be trading above its intrinsic value, noting that the company currently holds a "WEAK" financial health rating. The disposition of shares follows a recent acquisition event on July 2, 2026. On that date, Ms. Eylward acquired 920 shares of Imunon common stock. These shares were valued at $1.91 each, totaling $1,757, and were provided to her in lieu of cash compensation for a portion of her base salary. Following these concurrent transactions, Ms. Eylward's direct ownership in Imunon stands at 2,896 shares. The insider activity takes place within a period of notable financial and operational developments for the biotechnology firm. Imunon recently reported its first-quarter 2026 earnings, which fell significantly short of analyst expectations. The company posted an earnings per share (EPS) of -0.84, compared to the forecasted -0.1461, marking a substantial surprise of -474.95%. To support its operations, including its Phase 3 ovarian cancer trial, Imunon secured $10 million in financing. This capital injection includes 250 shares of non-redeemable, non-convertible preferred stock for $2.5 million and two secured promissory notes totaling $7.72 million. Operational updates indicate that the ongoing Phase 3 OVATION 3 clinical trial continues without modification, following a positive review by an independent Data Monitoring Committee. Furthermore, shareholders recently approved an amendment to the 2018 Stock Incentive Plan, increasing the number of shares available for awards by 1,000,000. During the same annual meeting, two directors were elected to the company’s board. These developments reflect Imunon’s ongoing efforts to advance its clinical trials and strategic initiatives. For deeper insights into IMNN’s financial health and insider activity, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities on InvestingPro.